Hydroxyethyl starch (HES) versus other fluid therapies: Effects on kidney function

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 7, 2013, Pages

  Mutter, Thomas C ^a   Ruth, Chelsea A ^a   Dart, Allison B ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HETASTARCH; HETASTARCH DERIVATIVE; PLASMA SUBSTITUTE;

ACUTE KIDNEY FAILURE; BLOOD VOLUME; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; FLUID RESUSCITATION; FLUID THERAPY; HUMAN; KIDNEY FUNCTION; META ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENAL REPLACEMENT THERAPY; REVIEW; SEPSIS; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT FAILURE; TREATMENT OUTCOME; URINE VOLUME; CHEMICALLY INDUCED; COMPARATIVE STUDY; CRITICAL ILLNESS; DRUG EFFECTS; KIDNEY; KIDNEY FAILURE; PHYSIOLOGY; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; METHODOLOGY;

ACUTE KIDNEY INJURY; CRITICAL ILLNESS; FLUID THERAPY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; KIDNEY; PLASMA SUBSTITUTES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENAL INSUFFICIENCY;

EID: 84883526173     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007594.pub3     Document Type: Review

References (117)

1. Abdel-Khalek EE, Arif SE. Randomized trial comparing human albumin and hydroxyethyl starch 6% as plasma expanders for treatment of patients with liver cirrhosis and tense ascites following large volume paracentesis. Arab Journal of Gastroenterology 2010;11(1):24-9. [EMBASE: 2010423152]
2. Akech SO, Jemutai J, Timbwa M, Kivaya E, Boga M, Fegan G, et al. Phase II trial on the use of Dextran 70 or starch for supportive therapy in Kenyan children with severe malaria. Critical Care Medicine 2010;38(8):1630-6. [MEDLINE: 20526196]
3. Akkucuk FG, Kanbak M, Ayhan B, Celebioglu B, Ulubay ZO, Aypar U. The effect of hydroxyethyl starch (130/0.4) as the priming solution on renal function in children undergoing cardiac surgery [abstract]. Applied Cardiopulmonary Pathophysiology 2012;16:191-2.
4. Altman C, Bernard B, Roulot D, Vitte RL, Ink O. Randomized comparative multicenter study of hydroxyethyl starch versus albumin as a plasma expander in cirrhotic patients with tense ascites treated with paracentesis. European Journal of Gastroenterology & Hepatology 1998;10(1):5-10. [MEDLINE: 9512946]
5. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. 2013 BMJ;346:f839. [MEDLINE: 23418281]
6. Siegemund M. Basel study for evaluation of starch (130;0.4) infusion in septic patients: BaSES (130;0.4) Trial. http://clinicaltrials.gov/ct2/show/NCT00273728 (accessed 5 July 2013).
7. Berard JP, Curt I, Piech JJ, Ruiz F. [Hydroxyéthylamidons versus gélatines: Impact sur le coût du remplissage dans un service de réanimation]. Annales Francaises d Anesthesie et de Reanimation 1995;14:R335.
8. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. New England Journal of Medicine 2008;358(2):125-39. [MEDLINE: 18184958]
9. Choi YS, Shim JK, Hong SW, Kim JC, Kwak YL. Comparing the effects of 5% albumin and 6% hydroxyethyl starch 130/0.4 on coagulation and inflammatory response when used as priming solutions for cardiopulmonary bypass. Minerva Anestesiologica 2010;76(8):584-91. [MEDLINE: 20661198]
10. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348(9042):1620-2. [MEDLINE: 8961992]
11. Dehne MG, Mühling J, Sablotzki A, Dehne K, Sucke N, Hempelmann G. Hydroxyethyl starch (HES) does not directly affect renal function in patients with no prior renal impairment. Journal of Clinical Anesthesia 2001;13(2):103-11. [MEDLINE: 11331169]
12. Diehl JT, Lester JL 3rd, Cosgrove DM. Clinical comparison of hetastarch and albumin in postoperative cardiac patients. Annals of Thoracic Surgery 1982;34(6):674-9. [MEDLINE: 6184023]
13. Dolecek M, Svoboda P, Kantorová I, Scheer P, Sas I, Bíbrová J, et al. Therapeutic influence of 20 % albumin versus 6% hydroxyethylstarch on extravascular lung water in septic patients: a randomized controlled trial. Hepato-Gastroenterology 2009;56(96):1622-8. [MEDLINE: 20214205]
14. Du XJ, Hu WM, Xia Q, Huang ZW, Chen GY, Jin XD, et al. Hydroxyethyl starch resuscitation reduces the risk of intra-abdominal hypertension in severe acute pancreatitis. Pancreas 2011;40(8):1220-5. [MEDLINE: 21775917]
15. Dubin A, Pozo M O, Casabella C A, Murias G, Palizas F, Moseinco M C, et al. Comparison of 6% hydroxyethyl starch 130/0.4 and saline solution for resuscitation of the microcirculation during the early goal-directed therapy of septic patients. Journal of Critical Care 2010;25(4):658-9. [MEDLINE: 20813485]
16. Ertmer C, Wulf H, Van Aken H, Friederich P, Mahl C, Bepperling F, et al. Efficacy and safety of 10% HES 130/0.4 versus 10% HES 200/0.5 for plasma volume expansion in cardiac surgery patients. Minerva Medica 2012;103(2):111-22. [MEDLINE: 22513516]
17. Fernández J, Monteagudo J, Bargallo X, Jiménez W, Bosch J, Arroyo V, et al. A randomized unblinded pilot study comparing albumin versus hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 2005;42(3):627-34. [MEDLINE: 16108036]
18. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, et al. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Canadian Journal of Anaesthesia 2000;47(12):1207-15. [MEDLINE: 11132743]
19. Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P. Safety of HES 130/0.4 (Voluven(R)) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial. European Journal of Anaesthesiology 2008;25(12):986-94. [MEDLINE: 18492315]
20. Guidet B, Martinet O, Boulain T, Philippart F, Poussel JF, Maizel J, et al. Assessment of hemodynamic efficacy and safety of 6% hydroxyethylstarch 130/0.4 vs. 0.9% NaCl fluid replacement in patients with severe sepsis: The CRYSTMAS study. Critical Care 2012;16(3):R94. [EMBASE: 2012329428]
21. Heradstveit BE, Guttormsen AB, Langørgen J, Hammersborg SM, Wentzel-Larsen T, Fanebust R, et al. Capillary leakage in post-cardiac arrest survivors during therapeutic hypothermia - a prospective, randomised study. Scandinavian Journal of Trauma Resuscitation and Emergency Medicine 2010;18:29. [MEDLINE: 20500876]
22. James MF, Michell WL, Joubert IA, Nicol AJ, Navsaria PH, Gillespie RS. Resuscitation with hydroxyethyl starch improves renal function and lactate clearance in penetrating trauma in a randomized controlled study: the FIRST trial (Fluids in Resuscitation of Severe Trauma). British Journal of Anaesthesia 2011;107(5):693-702. [MEDLINE: 21857015]
23. Jungheinrich C, Sauermann W, Bepperling F, Vogt NH. Volume efficacy and reduced influence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs in R&D 2004;5(1):1-9. [MEDLINE: 14725484]
24. Kasper SM, Meinert P, Kampe S, Görg C, Geisen C, Mehlhorn U, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. Anesthesiology 2003;99(1):42-7. [MEDLINE: 12826840]
25. Kumle B, Boldt J, Piper S, Schmidt C, Suttner S, Salopek S. The influence of different intravascular volume replacement regimens on renal function in the elderly. Anesthesia & Analgesia 1999;89(5):1124-30. [MEDLINE: 10553822]
26. Lee JS, Ahn SW, Song JW, Shim JK, Yoo KJ, Kwak YL. Effect of Hydroxyethyl Starch 130/0.4 on Blood Loss and Coagulation in Patients With Recent Exposure to Dual Antiplatelet Therapy Undergoing Off-Pump Coronary Artery Bypass Graft Surgery. Circulation Journal 2011;75(10):2397-402. [MEDLINE: 21817820]
27. London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH, et al. A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. Journal of Thoracic & Cardiovascular Surgery 1989;97(5):785-97. [MEDLINE: 2468978]
28. Magder S, Potter B, Fergusson D, Doucette S, De Verennes B. Importance of cardiac output measurements in the fluid after cardiac surgery study (FACS) [abstract]. Intensive Care Medicine 2010;36:S378. [EMBASE: 70291386 ]
29. Mahmood A, Gosling P, Vohra RK. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. British Journal of Surgery 2007;94(4):427-33. [MEDLINE: 17380548]
30. McIntyre LA, Fergusson D, Cook DJ, Rankin N, Dhingra V, Granton J, et al. Fluid resuscitation in the management of early septic shock (FINESS): a randomized controlled feasibility trial. Canadian Journal of Anaesthesia 2008;55(12):819-26. [MEDLINE: 19050085]
31. Mukhtar A, Aboulfetouh F, Obayah G, Salah M, Emam M, Khater Y, et al. The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Anesthesia & Analgesia 2009;109(3):924-30. [MEDLINE: 19690268]
32. Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. New England Journal of Medicine 2012;367(20):1901-11. [MEDLINE: 23075127]
33. Neff TA, Doelberg M, Jungheinrich C, Sauerland A, Spahn DR, Stocker R. Repetitive large-dose infusion of the novel hydroxyethyl starch 130/0.4 in patients with severe head injury. Anesthesia & Analgesia 2003;96(5):1453-9. [MEDLINE: 12707149]
34. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Aneman A, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. New England Journal of Medicine 2012;367(2):124-34. [MEDLINE: 22738085]
35. Protsenko DN, Leiderman IN, Grigor'ev EV, Kokarev EA, Levit AL, Gel'fand BR. Evaluation of the effectiveness and safety of synthetic colloid solutions in the treatment of severe abdominal sepsis: a randomized comparative study. Anesteziologiia i Reanimatologiia 2009, (5):9-13. [MEDLINE: 19938709]
36. Sander O, Reinhart K, Meier-Hellmann A. Equivalence of hydroxyethyl starch HES 130/0. 4 and HES 200/0. 5 for perioperative volume replacement in major gynaecological surgery. Acta Anaesthesiologica Scandinavica 2003;47(9):1151-8. [MEDLINE: 12969111]
37. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357(9260):911-6. [MEDLINE: 11289347]
38. Shatney CH, Deepika K, Militello PR, Majerus TC, Dawson RB. Efficacy of hetastarch in the resuscitation of patients with multisystem trauma and shock. Archives of Surgery 1983;118(7):804-9. [MEDLINE: 6190466]
39. Shmyrev V, Lomivorotov V, Ponomarev D. A word of caution for using hypertonic hydroxyethyl starch solution in valvular heart surgery [abstract]. Journal of Cardiothoracic & Vascular Anesthesia 2011;25(3 Suppl 1):S31-2. [EMBASE: 70428812]
40. Van der Linden PJ, De Hert SG, Deraedt D, Cromheecke S, De Decker K, De Paep R, et al. Hydroxyethyl starch 130/0.4 versus modified fluid gelatin for volume expansion in cardiac surgery patients: the effects on perioperative bleeding and transfusion needs. Anesthesia & Analgesia 2005;101(3):629-34. [MEDLINE: 16115963]
41. Vlachou E, Gosling P, Moiemen NS. Hydroxyethylstarch supplementation in burn resuscitation--a prospective randomised controlled trial. Burns 2010;36(7):984-91. [MEDLINE: 20558004]
42. Yang J, Wang WT, Yan LN, Xu MQ, Yang JY. Alternatives to albumin administration in hepatocellular carcinoma patients undergoing hepatectomy: An open, randomized clinical trial of efficacy and safety. Chinese Medical Journal 2011;124(10):1458-64. [EMBASE: 2011291975]
43. Yassen AM, Elshoubari MM, Salah T, Sultan AM, Flsadany MM, Wahab MA. Does co-Ad ministration of HES 130/0.4 to albumin 4% affect the transfusion requirements and coagulation profile in living-donor liver transplantation? [abstract]. Liver Transplantation 2011;Conference:S133. [EMBASE: 70787513]
44. Aksun M, Damar E, Goktogan T, Yilmaz E, Aran G, Sencan A, et al. Haemodynamic, metabolic and haemostatic effects of 6% HES 130/0.4 usage as a priming solution in addition to Ringer's solution in CABG operations. Journal of Cardiothoracic & Vascular Anesthesia 2009;23(3 Suppl 1):S36-7. [EMBASE: 70261994]
45. Allison KP, Gosling P, Jones S, Pallister I, Porter KM. Randomized trial of hydroxyethyl starch versus gelatine for trauma resuscitation. Journal of Trauma 1999;47(6):1114-21. [MEDLINE: 10608543]
46. Ando Y, Terao Y, Fukusaki M, Yamashita K, Takada M, Tanabe T, et al. Influence of low-molecular-weight hydroxyethyl starch on microvascular permeability in patients undergoing abdominal surgery: comparison with crystalloid. Journal of Anesthesia 2008;22(4):391-6. [MEDLINE: 19011778]
47. Beyer R, Harmening U, Rittmeyer O, Zielmann S, Mielck F, Kazmaier S, et al. Use of modified fluid gelatin and hydroxyethyl starch for colloidal volume replacement in major orthopaedic surgery. British Journal of Anaesthesia 1997;78(1):44-50. [MEDLINE: 9059203]
48. Boldt J, Knothe C, Schindler E, Hammermann H, Dapper F, Hempelmann G. Volume replacement with hydroxyethyl starch solution in children. British Journal of Anaesthesia 1993;70(6):661-5. [MEDLINE: 7687142]
49. Boldt J, Muller M, Mentges D, Papsdorf M, Hempelmann G. Volume therapy in the critically ill: is there a difference?. Intensive Care Medicine 1998;24(1):28-36. [MEDLINE: 9503219]
50. Boldt J, Lehmann A, Rompert R, Haisch G, Isgro F. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. Journal of Cardiothoracic & Vascular Anesthesia 2000;14(3):264-8. [MEDLINE: 10890478]
51. Boldt J, Suttner S, Kumle B, Hüttner I. Cost analysis of different volume replacement strategies in anesthesia. Infusionstherapie und Transfusionsmedizin 2000;27(1):38-43. [EMBASE: 2000065818]
52. Boldt J, Brenner T, Lehmann A, Lang J, Kumle B, Werling C. Influence of two different volume replacement regimens on renal function in elderly patients undergoing cardiac surgery: comparison of a new starch preparation with gelatin. Intensive Care Medicine 2003;29(5):763-9. [MEDLINE: 12665995]
53. Boldt J, Scholhorn T, Mayer J, Piper S, Suttner S. The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery. Anesthesia & Analgesia 2006;103(1):191-9. [MEDLINE: 16790652]
54. Boldt J, Brosch C, Ducke M, Papsdorf M, Lehmann A. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Critical Care Medicine 2007;35(12):2740-6. [MEDLINE: 17893629]
55. Boldt J, Schollhorn T, Munchbach J, Pabsdorf M. A total balanced volume replacement strategy using a new balanced hydoxyethyl starch preparation (6% HES 130/0.42) in patients undergoing major abdominal surgery. European Journal of Anaesthesiology 2007;24(3):267-75. [MEDLINE: 17054812]
56. Boldt J, Brosch C, Rohm K, Papsdorf M, Mengistu A. Comparison of the effects of gelatin and a modern hydroxyethyl starch solution on renal function and inflammatory response in elderly cardiac surgery patients. British Journal of Anaesthesia 2008;100(4):457-64. [MEDLINE: 18305082]
57. Boldt J, Suttner S, Brosch C, Lehmann A, Rohm K, Mengistu A. Cardiopulmonary bypass priming using a high dose of a balanced hydroxyethyl starch versus an albumin-based priming strategy. Anesthesia & Analgesia 2009;109(6):1752-62. [MEDLINE: 19923501]
58. Boldt J, Mayer J, Brosch C, Lehmann A, Mengistu A. Volume replacement with a balanced hydroxyethyl starch (HES) preparation in cardiac surgery patients. Journal of Cardiothoracic & Vascular Anesthesia 2010;24(3):399-407. [MEDLINE: 20510247]
59. Chen J, Han CM, Xia SC, Tang ZJ, Su SJ. Evaluation of effectiveness and safety of a new hydroxyethyl starch used in resuscitation of burn shock. Zhonghua Shao Shang Za Zhi 2006;22(5):333-6. [MEDLINE: 17283875]
60. Dehne MG, Mühling J, Sablotzki A, Papke G, Kuntzsch U, Hempelmann G. Effect of hydroxyethyl starch on renal function in intensive-care patients [Einfluss von Hydroxyethylstarke-Losung auf die Nierenfunktion bei operativen Intensivpatienten]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie 1997;32(6):348-54. [MEDLINE: 9333329]
61. Hanart C, Khalife M, De Villé A, Otte F, De Hert S, Van der Linden P. Perioperative volume replacement in children undergoing cardiac surgery: albumin versus hydroxyethyl starch 130/0.4. Critical Care Medicine 2009;37(2):696-701. [MEDLINE: 19114887]
62. Kalayanarooj S. Choice of colloidal solutions in dengue hemorrhagic fever patients. Journal of the Medical Association of Thailand 2008;91(Suppl 3):S97-103. [MEDLINE: 19253503]
63. Kulla M, Weidhase R, Lampl L. Hydroxyethyl starch 6% 130/0.42 in acetate-buffered Ringer's solution as a part of a balanced-volume resuscitation in abdominal surgery [Hydroxyethylstarke 6% 130/0, 42 in Ringerazetat als komponente eines balancierten volumenersatzes in der abdominalchirurgie]. Anasthesiologie und Intensivmedizin 2008;49(1):7-18. [EMBASE: 2008062037]
64. Kvalheim VL, Farstad M, Steien E, Mongstad A, Borge BA, Kvitting PM, et al. Infusion of hypertonic saline/starch during cardiopulmonary bypass reduces fluid overload and may impact cardiac function. Acta Anaesthesiologica Scandinavica 2010;54(4):485-93. [MEDLINE: 19878097]
65. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P. Voluven, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesthesia & Analgesia 2001;92(4):855-62. [MEDLINE: 11273914]
66. Liet JM, Bellouin AS, Boscher C, Lejus C, Roze JC. Plasma volume expansion by medium molecular weight hydroxyethyl starch in neonates: a pilot study. Pediatric Critical Care Medicine 2003;4(3):305-7. [MEDLINE: 12831411]
67. NCT00576849 Phase 4 study of a total balanced volume replacement regimen in elderly cardiac surgery patients. www.clinicaltrials.gov/ct2/show/NCT00576849 (accessed 5 July 2013). [CLINICALTRIALS.GOV: NCT00576849]
68. Ooi JS, Ramzisham AR, Zamrin MD. Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery?. Asian Cardiovascular & Thoracic Annals 2009;17(4):368-72. [MEDLINE: 19713332]
69. Petrikov SS, Solodov AA, Titova IuV, Davydov BV, Krylov VV. Tactics of infusion therapy in the acute period of intracranial hemorrhages. Anesteziologiia i Reanimatologiia 2008, (2):36-9. [MEDLINE: 18540460]
70. Sade RM, Stroud MR, Crawford FA Jr, Kratz JM, Dearing JP, Bartles DM. A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer's solution as priming fluid for cardiopulmonary bypass. Journal of Thoracic & Cardiovascular Surgery 1985;89(5):713-22. [MEDLINE: 2581099]
71. Schewior L, Frei U, Neuhaus P, Junge G. Treatment and impact of hepatorenal syndrome for patients on waiting list for liver transplantation [abstract]. Liver Transplantation 2008;14(7 (Suppl 1)):S219.
72. Shahbazi S, Zeighami D, Allahyary E, Alipour A, Esmaeeli M J, Ghaneie M. Effect of colloid versus crystalloid administration of cardiopulmonary bypass prime solution on tissue and organ perfusion. Iranian Cardiovascular Research Journal 2011;5(1):24-31.
73. Tiryakioglu O, Yildiz G, Vural H, Goncu T, Ozyazicioglu A, Yavuz Ş. Hydroxyethyl starch versus Ringer solution in cardiopulmonary bypass prime solutions (a randomized controlled trial). Journal of Cardiothoracic Surgery 2008;3:45. [MEDLINE: 18620591]
74. Vernetta D, Alvarez A, Churruca I, Hernando D, Puigvert F. The effects of hydroxyethyl 130/0.4 (Voluven) on renal function in laparoscopic nephrectomy [abstract]. British Journal of Anaesthesia 2012;108:ii13-4. [EMBASE: 70718972]
75. Vogt N, Bothner U, Brinkmann A, de Petriconi R, Georgieff M. Peri-operative tolerance to large-dose 6% HES 200/0.5 in major urological procedures compared with 5% human albumin. Anaesthesia 1999;54(2):121-7. [MEDLINE: 10215706]
76. Wu Y, Wu AS, Wang J, Tian M, Jia XY, Rui Y, et al. Effects of the novel 6% hydroxyethyl starch 130/0.4 on renal function of recipients in living-related kidney transplantation. Chinese Medical Journal 2010;123(21):3079-83. [MEDLINE: 21162959]
77. American Thoracic Society. Evidence-based colloid use in the critically ill: American Thoracic Society Consensus Statement. American Journal of Respiratory & Critical Care Medicine 2004;170(11):1247-59. [MEDLINE: 15563641]
78. Bagshaw SM, Bellomo R. The influence of volume management on outcome. Current Opinion in Critical Care 2007;13(5):541-8. [MEDLINE: 17762233]
79. Barron ME, Mahlon MW, Navickis RJ. A systematic review of the comparative safety of colloids. Archives of Surgery 2004;139(5):552-63. [MEDLINE: 15136357]
80. Belli LS, De Carlis L, Del Favero E, Civati G, Brando B, Romani F, et al. The role of donor and recipient factors in initial renal graft non-function. Transplantation Proceedings 1988;20(5):861-4. [MEDLINE: 3055518]
81. Bellmann R, Feistritzer C, Wiedermann CJ. Effect of molecular weight and substitution on tissue uptake of hydroxyethyl starch: a meta-analysis of clinical studies. Clinical Pharmacokinetics 2012;51(4):225-36. [MEDLINE: 22420578]
82. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative Workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Critical Care 2004;8(4):R204-12. [MEDLINE: 15312219]
83. Blasco V, Leone M, Antonini F, Geissler A, Albanese J, Martin C. Comparison of the novel hydroxyethylstarch 130/0.4 and hydroxyethylstarch 200/0.6 in brain-dead donor resuscitation on renal function after transplantation. British Journal of Anaesthesia 2008;100(4):504-8. [MEDLINE: 18256055]
84. Bork K. Pruritus precipitated by hydroxyethyl starch: a review. British Journal of Dermatology 2005;152(1):3-12. [MEDLINE: 15656795]
85. Cerda J. Oliguria: an earlier and accurate biomarker of acute kidney injury?. Kidney International 2011;80(7):699-701. [MEDLINE: 21918558]
86. Cotton BA, Guy JS, Morris JA Jr, Abumrad NN. The cellular, metabolic and systemic consequences of aggressive fluid resuscitation strategies. Shock 2006;26(2):115-21. [MEDLINE: 16878017]
87. Cruz DN, Bolgan I, Perazella MA, Bonello M, de Cal M, Corradi V, et al. North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEiPHROS-AKI): targeting the problem with the RIFLE Criteria. Clinical Journal of The American Society of Nephrology: CJASN 2007;2(3):418-25. [MEDLINE: 17699446]
88. Deman A, Peeters P, Sennesael J. Hydroxyethyl starch does not impair immediate renal function in kidney transplant recipients: a retrospective, multicentre analysis. Nephrology Dialysis Transplantation 1999;14(6):1517-20. [MEDLINE: 10383017]
89. Anonymous Editors-in-Chief statement regarding published clinical trials conducted without IRB approval by Joachim Boldt. Minerva Anestesiologica 2011;77(5):562-3. [MEDLINE: 21540815]
90. Ferber HP, Nitsch E, Forster H. Studies on hydroxyethyl starch. Part II: Changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers. Arzneimittel-Forschung 1985;35(3):615-22. [MEDLINE: 2581591]
91. Giral, M, Bertola JP, Foucher Y, Villers D, Bironneau E, Blanloeil Y, et al. Effect of brain-dead donor resuscitation on delayed graft function: results of a monocentric analysis. Transplantation 2007;83(9):1174-81. [MEDLINE: 17496532]
92. Grocott MP, Mythen MG, Gan TJ. Perioperative fluid management and clinical outcomes in adults. Anesthesia & Analgesia 2005;100(4):1093-106. [MEDLINE: 15781528]
93. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013;346:f839. [MEDLINE: 23418281]
94. Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl start (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesthesia & Analgesia 2011;112(3):635-45. [MEDLINE: 21304149]
95. Hetzel GR, Klein B, Brause M, Westhoff A, Willers R, Sandmann W, et al. Risk factors for delayed graft function after renal transplantation and their significance for long- term clinical outcome. Transplant International 2002;15(1):10-16. [MEDLINE: 11875607]
96. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60. [MEDLINE: 12958120]
97. Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
98. Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clinical Pharmacokinetics 2005;44(7):681-99. [MEDLINE: 15966753]
99. Kellum JA, Bellomo R, Ronco C. Definition and classification of acute kidney injury. Nephron 2008;109(4):c182-7. [MEDLINE: 18802365]
100. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342(8865):248-9. [MEDLINE: 7686994]
101. Lukasewitz P, Kroh U, Löwenstein O, Kramer M, Lennartz H. Quantitative measurement regarding the tissue storage of middle molecular hydroxyethyl starch 200/0, 5 in patients with multiple organ failure [Quantitative Untersuchungen zur Gewebsspeicherung von mittelmolekularer Hydroxyethylstarke 200/0, 5 bei Patienten mit Multiorganversagen]. Journal für Anasthesie und Intensivbehandlung 1998;3:42-6.
102. McIntyre LA, Hebert PC, Fergusson D, Cook DJ, Aziz A, for the Canadian Critical Care Trials Group. A survey of Canadian intensivists' resuscitation practices in early septic shock. Critical Care 2007;11(4):R74. [MEDLINE: 17623059]
103. Metze D, Reimann S, Szepfalusi Z, Bohle B, Kraft D, Luger TA. Persistent pruritus after hydroxyethyl starch infusion therapy: a result of long-term storage in cutaneous nerves. British Journal of Dermatology 1997;136(4):553-9. [MEDLINE: 9155957]
104. Miletin MS, Stewart TE, Norton PG. Influences on physicians' choices of intravenous colloids. Intensive Care Medicine 2002;28(7):917-24. [MEDLINE: 12122530]
105. Moran M, Kaspner C. Acute renal failure associated with elevated plasma oncotic pressure. New England Journal of Medicine 1987;317(3):150-3. [MEDLINE: 2439908]
106. Pfaff WW, Howard RJ, Patton PR, Adams VR, Rosen CB, Reed AI. Delayed graft function after renal transplantation. Transplantation 1998;65(2):219-23. [MEDLINE: 9458018]
107. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. Kidney International 2008;73(5):538-46. [MEDLINE: 18160961]
108. Schortgen F, Deye N, Brochard L, for the CRYCO Study Group. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Medicine 2004;30(12):2222-9. [MEDLINE: 15452693]
109. Sear JW. Kidney dysfunction in the postoperative period. British Journal of Anaesthesia 2005;95(1):20-32. [MEDLINE: 15531622]
110. Sirtl C, Laubenthal H, Zumtobel V, Kraft D, Jurecka W. Tissue deposits of hydroxyethyl starch (HES): dose-dependent and time-related. British Journal of Anaesthesia 1999;82(4):510-5. [MEDLINE: 10472213]
111. Suri D, Meyer TW. Influence of donor factors on early function of graft kidneys. Journal of the American Society of Nephrology 1999;10(6):1317-23. [MEDLINE: 10361871]
112. Waikar SS, Liu KD, Chertow GM. The incidence and prognostic significance of acute kidney injury. Current Opinion in Nephrology & Hypertension 2007;16(3):227-36. [MEDLINE: 17420666]
113. Wiedermann CJ. Hydroxyethyl starch--can the safety problems be ignored?. Wiener Klinische Wochenschrift 2004;116(17-18):583-94. [MEDLINE: 15515874]
114. Wlodzimirow KA, Abu-Hanna A, Slabbekoorn M, Chamuleau RA, Schultz MJ, Bouman CS. A comparison of RIFLE with and without urine output criteria for acute kidney injury in critically ill patients. Critical Care 2012;16(5):R200. [EMBASE: 2012750959]
115. Zarychanski R, Abou-Setta AM, Turgeon AF, Houston BL, McIntyre L, Marshall JC, et al. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and meta-analysis. JAMA 2013;309(7):678-88. [MEDLINE: 23423413]
116. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database of Systematic Reviews 2009, Issue 1. [DOI: 10.1002/14651858.CD007594]
117. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fluid therapies: effects on kidney function. Cochrane Database of Systematic Reviews 2010, Issue 1. [DOI: 10.1002/14651858.CD007594.pub2]